Novartis drug Afinitor® approved by FDA as first medication for children and adu

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for patients with subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), who require therapeutic intervention but are not candidates for curative surgical resection.Download the media release